Literature DB >> 306357

The characterization of somatostatin-like immunoreactivity in human serum.

S Kronheim, M Berelowitz, B L Pimstone.   

Abstract

We describe the characterization of somatostatin-like immunoreactivity (SRIF-LI) found by radioimmunoassay (RIA) to be present in normal human serum. Degradation by serum of 125I-Tyr1 SRIF in the assay, as assessed by chromatoelectrophoresis and immunoprecipitation, was overcome by using EDTA in the assay buffer and Trasylol in the blood samples. Serum samples thus obtained from 48 normal subjects revealed a bimodal distribution of SRIF-LI; 92 per cent (group 1) had a mean level of 0.274 +/- 0.009 ng. per milliliter. What was measured in these sera showed identity to synthetic SRIF on serial dilutions, Sephadex G-25 chromatography, and thin-layer chromatography, and it was shown to be immunoreactive by an antibody-Sepharose affinity system. Higher levels (1.0 +/- 0.041 ng. per milliliter) were found in 8 per cent of the sera; 50 per cent of this material behaved identically as serum SRIF-LI from group 1. The remainder proved to be heterogeneous, consisting of two peaks of large molecular weight, both of which shared immunologic identity with synthetic SRIF as shown by binding to the antibody-Sepharose affinity system. Their further nature is unknown.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 306357     DOI: 10.2337/diab.27.5.523

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  11 in total

Review 1.  Multiple forms of gastroenteropancreatic hormones.

Authors:  G B Irvine; R F Murphy
Journal:  Gut       Date:  1981-12       Impact factor: 23.059

2.  Hepatic and renal metabolism of somatostatin-like immunoreactivity. Simultaneous assessment in the dog.

Authors:  K S Polonsky; J B Jaspan; M Berelowitz; D S Emmanouel; J Dhorajiwala
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

3.  Clearance of immunoreactive somatostatin by perfused rat liver.

Authors:  H Sacks; L C Terry
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

4.  Isolation and structure of pro-somatostatin: a putative somatostatin precursor from pig hypothalamus.

Authors:  A V Schally; W Y Huang; R C Chang; A Arimura; T W Redding; R P Millar; M W Hunkapiller; L E Hood
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

5.  Circulating prosomatostatin-derived peptides. Differential responses to food ingestion.

Authors:  J W Ensinck; E C Laschansky; R E Vogel; D A Simonowitz; B A Roos; B H Francis
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

6.  Influence of methionine-enkephalin analogue (FK-33-824) on the secretion of pancreatic hormones.

Authors:  K Sekiya; A Funakoshi; H Shinozaki; H Nawata; K Kato; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1985-06

7.  Properties of endogenous somatostatin-like immunoreactivity and synthetic somatostatin in dog plasma.

Authors:  J M Conlon; C B Srikant; E Ipp; V Schusdziarra; W Vale; R H Unger
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

8.  Effect of caerulein administration on portal plasma somatostatin in dogs.

Authors:  J Kasanuki; S Fujimoto; H Makino; A Kanatsuka; T Imaizumi; H Koseki; R Kaneko; Y Tokumasa; S Yoshida
Journal:  Gastroenterol Jpn       Date:  1984-06

9.  Plasma somatostatin 28 increases in response to feeding in man.

Authors:  K S Polonsky; S E Shoelson; H M Docherty
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

10.  Measurement of growth hormone-releasing hormone and somatostatin in hypothalamic-portal plasma of unanesthetized sheep. Spontaneous secretion and response to insulin-induced hypoglycemia.

Authors:  L A Frohman; T R Downs; I J Clarke; G B Thomas
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.